Zentalis Pharmaceuticals

ZNTL

Market cap $101M

1.40 USD

0.00

At close Updated Dec 22, 4:00 PM EST

Pre-market

After hours

1.41

+0.01

0.71%

1 day

5 days

1.45%

1 month

0.72%

3 months

-7.89%

6 months

7.69%

Year to date

-53.33%

1 year

-55.97%

5 years

-97.36%

10 years

-93.97%

About: Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Employees: 166

Healthcare Biotechnology